Travere Therapeutics Hits New 52-Week High of $53.87, Up 640%

Travere Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 53.87 on June 15, 2026. This achievement marks a remarkable 640.03% increase in the company's stock price over the past year, significantly outperforming the S&P 500, which has seen a gain of 26.39% during the same period. With a market capitalization of USD 2,514 million, Travere Therapeutics continues to make strides in its industry. Despite being a loss-making entity, the company has demonstrated resilience and growth potential, as reflected in its impressive stock performance. The stock's 52-week low was recorded at USD 13.88, highlighting the substantial upward movement it has experienced. Key financial metrics include a debt-to-equity ratio of -0.05 and a return on equity of -43.77%, indicating the company's current financial positioning. As Travere Therapeutics continues to navigate the competitive landscape of pharmaceuticals and biotechnology, its recent performance underscores its evolving market presence.